Insmed Reports Second Quarter 2021 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Insmed (INSM) Misses Q2 EPS by 22c
August 5, 2021 8:12 AM EDTInsmed (NASDAQ: INSM) reported Q2 EPS of ($1.07), $0.22 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $45.4 million versus the consensus estimate of $43.72 million.
"Insmed made meaningful progress in the second quarter of 2021, with important achievements across our four pillars-ARIKAYCE, brensocatib,... More
